Advice
following a resubmission
azacitidine (Vidaza®) is accepted for use within NHS Scotland.
Indication under review: for treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (SCT) with intermediate-2 and high-risk myelodysplastic syndrome (MDS), chronic myelomonocytic leukaemia (CMML) or acute myeloid leukaemia (AML).
Azacitidine therapy produced a significant increase in overall survival compared with conventional care regimens in previously untreated higher-risk MDS patients.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of azacitidine. This SMC advice is contingent upon the continuing availability of the PAS in NHS Scotland.
Download detailed advice130KB (PDF)
Medicine details
- Medicine name:
- azacitidine (Vidaza)
- SMC ID:
- 589/09
- Indication:
- Treatment of adult patients not eligible for haematopoietic stem cell transplantation with: myelodysplastic syndrome / chronic myelomonocytic leukaemia / acute myeloid leukaemia
- Pharmaceutical company
- Celgene Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 12 September 2011